BRPI0814975A2 - Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla - Google Patents
Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltiplaInfo
- Publication number
- BRPI0814975A2 BRPI0814975A2 BRPI0814975-5A2A BRPI0814975A BRPI0814975A2 BR PI0814975 A2 BRPI0814975 A2 BR PI0814975A2 BR PI0814975 A BRPI0814975 A BR PI0814975A BR PI0814975 A2 BRPI0814975 A2 BR PI0814975A2
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- pyrimidine
- bind
- receptor
- phosphate
- Prior art date
Links
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 2
- JLTSEIZANHBJML-UHFFFAOYSA-N 6-aminopyrimidine-4-carboxamide Chemical class NC(=O)C1=CC(N)=NC=N1 JLTSEIZANHBJML-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113992 | 2007-08-08 | ||
| US96486407P | 2007-08-15 | 2007-08-15 | |
| PCT/EP2008/059933 WO2009019167A1 (en) | 2007-08-08 | 2008-07-29 | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814975A2 true BRPI0814975A2 (pt) | 2015-02-03 |
Family
ID=38985492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814975-5A2A BRPI0814975A2 (pt) | 2007-08-08 | 2008-07-29 | Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8399448B2 (pt) |
| EP (1) | EP2183224B1 (pt) |
| JP (1) | JP5508265B2 (pt) |
| KR (1) | KR20100051849A (pt) |
| CN (1) | CN101790519B (pt) |
| AR (1) | AR067877A1 (pt) |
| AU (1) | AU2008285722B2 (pt) |
| BR (1) | BRPI0814975A2 (pt) |
| CA (1) | CA2696565C (pt) |
| EA (1) | EA201070238A1 (pt) |
| ES (1) | ES2445405T3 (pt) |
| IL (1) | IL203578A (pt) |
| MX (1) | MX2010001446A (pt) |
| WO (1) | WO2009019167A1 (pt) |
| ZA (1) | ZA201000585B (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2360929T3 (es) * | 2007-09-20 | 2011-06-10 | Amgen Inc. | Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios. |
| HRP20161133T1 (hr) | 2008-07-23 | 2016-12-02 | Arena Pharmaceuticals, Inc. | DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| US9073888B2 (en) | 2009-10-23 | 2015-07-07 | Allergan, Inc. | Coumarin compounds as receptor modulators with therapeutic utility |
| CA2786994C (en) | 2010-01-27 | 2018-01-16 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| WO2011113309A1 (en) * | 2010-03-17 | 2011-09-22 | Glaxo Group Limited | Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists |
| CN103619828A (zh) * | 2011-04-14 | 2014-03-05 | 阿勒根公司 | 作为1-磷酸鞘氨醇受体调节剂的苯基双环甲基胺衍生物 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014130572A1 (en) * | 2013-02-21 | 2014-08-28 | Allergan, Inc. | Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators |
| CN103408501B (zh) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | 苄基嘧啶衍生物、其制备方法及其医药用途 |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| BR112016015983A2 (pt) * | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica |
| SMT202400142T1 (it) | 2014-01-13 | 2024-05-14 | Aurigene Oncology Ltd | Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro |
| KR101499007B1 (ko) * | 2014-04-24 | 2015-03-05 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| MX2020003666A (es) | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
| JP7526673B2 (ja) | 2018-02-20 | 2024-08-01 | インサイト・コーポレイション | がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| BR112022010127A2 (pt) * | 2019-11-25 | 2022-09-06 | Gain Therapeutics Sa | Compostos de arila e heteroarila e usos terapêuticos dos mesmos em condições associadas à alteração da atividade de galatocerebrosidase |
| US12178821B2 (en) | 2021-04-08 | 2024-12-31 | Curis, Inc. | Combination therapies for the treatment of cancer |
| GB202213310D0 (en) * | 2022-09-12 | 2022-10-26 | Benevolentai Cambridge Ltd | New compounds and methods |
| WO2024126777A1 (en) * | 2022-12-16 | 2024-06-20 | Astrazeneca Ab | Heteroaromatic compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2211172T3 (es) * | 1998-09-25 | 2004-07-01 | Astrazeneca Ab | Derivados de benzamida y su utilizacion como inhibidores de citoquinas. |
| WO2002096903A2 (fr) * | 2001-05-28 | 2002-12-05 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
| US7220764B2 (en) * | 2002-06-17 | 2007-05-22 | The Pennsylvania State University Research Foundation | Sphingosine kinase inhibitors |
| TW200524880A (en) | 2003-10-21 | 2005-08-01 | Sankyo Co | Pyrimidine compounds |
| EP1694659B8 (en) | 2003-12-19 | 2008-10-08 | Schering Corporation | Thiadiazoles as cxc- and cc- chemokine receptor ligands |
| WO2006053109A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
-
2008
- 2008-07-29 BR BRPI0814975-5A2A patent/BRPI0814975A2/pt not_active IP Right Cessation
- 2008-07-29 CN CN2008801020927A patent/CN101790519B/zh not_active Expired - Fee Related
- 2008-07-29 JP JP2010519431A patent/JP5508265B2/ja not_active Expired - Fee Related
- 2008-07-29 AU AU2008285722A patent/AU2008285722B2/en not_active Ceased
- 2008-07-29 US US12/671,996 patent/US8399448B2/en not_active Expired - Fee Related
- 2008-07-29 MX MX2010001446A patent/MX2010001446A/es not_active Application Discontinuation
- 2008-07-29 ES ES08775369.5T patent/ES2445405T3/es active Active
- 2008-07-29 KR KR1020107005173A patent/KR20100051849A/ko not_active Withdrawn
- 2008-07-29 EP EP08775369.5A patent/EP2183224B1/en active Active
- 2008-07-29 EA EA201070238A patent/EA201070238A1/ru unknown
- 2008-07-29 CA CA2696565A patent/CA2696565C/en not_active Expired - Fee Related
- 2008-07-29 WO PCT/EP2008/059933 patent/WO2009019167A1/en not_active Ceased
- 2008-08-07 AR ARP080103456A patent/AR067877A1/es not_active Application Discontinuation
-
2010
- 2010-01-26 ZA ZA2010/00585A patent/ZA201000585B/en unknown
- 2010-01-28 IL IL203578A patent/IL203578A/en active IP Right Grant
-
2012
- 2012-12-12 US US13/711,893 patent/US9150519B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2183224B1 (en) | 2013-11-06 |
| CN101790519A (zh) | 2010-07-28 |
| CA2696565C (en) | 2017-02-14 |
| CA2696565A1 (en) | 2009-02-12 |
| US20100210619A1 (en) | 2010-08-19 |
| AU2008285722A1 (en) | 2009-02-12 |
| EA201070238A1 (ru) | 2010-08-30 |
| US8399448B2 (en) | 2013-03-19 |
| AU2008285722B2 (en) | 2013-06-20 |
| KR20100051849A (ko) | 2010-05-18 |
| ES2445405T3 (es) | 2014-03-03 |
| WO2009019167A1 (en) | 2009-02-12 |
| CN101790519B (zh) | 2013-10-16 |
| IL203578A (en) | 2014-02-27 |
| JP2010535734A (ja) | 2010-11-25 |
| MX2010001446A (es) | 2010-03-01 |
| EP2183224A1 (en) | 2010-05-12 |
| JP5508265B2 (ja) | 2014-05-28 |
| ZA201000585B (en) | 2011-04-28 |
| US9150519B2 (en) | 2015-10-06 |
| US20130109669A1 (en) | 2013-05-02 |
| AR067877A1 (es) | 2009-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201000585B (en) | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis | |
| CY2020014I1 (el) | Σχημα δοσολογιας ενος αγωνιστη υποδοχεα s1p | |
| BRPI0819690A2 (pt) | Método para tratar um paciente que sofre de doença do fígado gorduroso | |
| PT2185157T (pt) | Composições de dhea para o tratamento da menopausa | |
| BRPI0915282A2 (pt) | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade | |
| PL15177166T1 (pl) | Modulatory receptora s1p do leczenia stwardnienia rozsianego | |
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| BRPI0916862A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias | |
| BR112012004166A2 (pt) | colocação otimizada de cândula para aplicação de agentes terapêuticos ao cérebro | |
| BRPI0908217A2 (pt) | Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia | |
| BRPI0818161A2 (pt) | composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p) | |
| BRPI0915439A2 (pt) | composição tópica para o tratamento de ceratose actínica | |
| PT2355851T (pt) | Novos lípidos e composições para a administração de agentes terapêuticos | |
| CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
| BRPI0820519A2 (pt) | intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário | |
| PT2205720T (pt) | Composições para tratamento de esclerose múltipla | |
| BRPI0813670A2 (pt) | Compostos para tratamento | |
| BRPI0922619A2 (pt) | compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento | |
| BRPI0817777A2 (pt) | Composição cosmética que compreende partículas de captura de sólido para liberação sustentada de materias voláteis | |
| BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
| CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
| BRPI0814043A2 (pt) | composição farmacêutica para aplicação tópica de compostos pouco solúveis | |
| BRPI0813788A2 (pt) | Processo para preparação de metacrilato de alila | |
| BRPI0914139A2 (pt) | composições pediátricas para o tratamento de esclerose múltipla | |
| BRPI0912512A2 (pt) | Processo para a preparação de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |